Orlando Sevillano

Dr. Orlando Sevillano

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
ENEduardo Navarrete-Bencomo
Eduardo Navarrete-Bencomo
Anthony Vladimir Campos SeguraAnthony Vladimir Campos Segura
Anthony Vladimir Campos Segura
OSOrlando Sevillano
Orlando Sevillano
AMAna Mayanga
Ana Mayanga
JBJosé Luis Buleje
José Luis Buleje
Alexis Murillo CarrascoAlexis Murillo Carrasco
Alexis Murillo Carrasco
Motivation: The Cancer Cell Line Encyclopedia (CCLE), launched in 2008, systematically organizes multi-omic and pharmacological data from over 1000 cancer cell lines with molecular dependency maps accessible through the DepMap tool. However, DepMap lacks tools for systematic comparison of mRNAs, miRNAs, proteins, and metabolites, as well as their links to drug responses and gene signatures. Extracting this data externally requires bioinformatics expertise, limiting access for wet-lab researchers. Results: We developed ShinyTHOR, a web app for intuitive access to multi-omic (transcriptomic, metabolomic, methylomic, proteomic, and miRNomic) and drug-related data. It integrates datasets from CCLE, miRTarBase, circInteractome, and the Genomics of Drug Sensitivity in Cancer. ShinyTHOR includes six modules: (1) identifying top/bottom ten cell lines by marker expression or drug IC50, (2) single-sample Gene Set Enrichment Analysis (ssGSEA), (3) multi-analyte expression evaluation, (4) miRNA-target interactions across cancer types, (5) miRNA impact on mRNA translation via protein levels, and (6) circRNA/miRNA modulation. To validate its utility, we applied ShinyTHOR to a gastric cancer prognosis study (GES7). Availability and implementation: ShinyTHOR is freely accessible for non-commercial use at https://alexismurillo.shinyapps.io/ShinyThor, with source code available at https://github.com/Murillo22/ShinyThor.

4 May 2021 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
LRLuiza Campos Reis
Luiza Campos Reis
ESEduardo Milton Ramos Sanchez
Eduardo Milton Ramos Sanchez
FAFernanda N. Araujo
Fernanda N. Araujo
ALAriane F. Leal
Ariane F. Leal
COChristiane Yumi Ozaki
Christiane Yumi Ozaki
HGHiro Goto
Hiro Goto
Leishmaniases are diseases caused by several Leishmania species, and many factors contribute to the development of the infection. Because the adaptive immune response does not fully explain the outcome of Leishmania infection and considering that the initial events are crucial in the establishment of the infection, we investigated one of the growth factors, the insulin-like growth factor-I (IGF-I), found in circulation and produced by different cells including macrophages and present in the skin where the parasite is inoculated. Here, we review the role of IGF-I in leishmaniasis experimental models and human patients. IGF-I induces the growth of different Leishmania species in vitro and alters the disease outcome increasing the parasite load and lesion size, especially in L. major- and L. amazonensis-infected mouse leishmaniasis. IGF-I affects the parasite interacting with the IGF-I receptor present on Leishmania. During Leishmania-macrophage interaction, IGF-I acts on the arginine metabolic pathway, resulting in polyamine production both in macrophages and Leishmania. IGF-I and cytokines interact with reciprocal influences on their expression. IL-4 is a hallmark of susceptibility to L. major in murine leishmaniasis, but we observed that IGF-I operates astoundingly as an effector element of the IL-4. Approaching human leishmaniasis, patients with mucosal, disseminated, and visceral diseases presented surprisingly low IGF-I serum levels, suggesting diverse effects than parasite growth. We observed that low IGF-I levels might contribute to the inflammatory response persistence and delayed lesion healing in human cutaneous leishmaniasis and the anemia development in visceral leishmaniasis. We must highlight the complexity of infection revealed depending on the Leishmania species and the parasites developmental stages. Because IGF-I exerts pleiotropic effects on the biology of interaction and disease pathogenesis, IGF-I turns up as an attractive tool to explore biological and pathogenic processes underlying infection development. IGF-I pleiotropic effects open further the possibility of approaching IGF-I as a therapeutical target.

15 August 2020 in Bionatura
Verified
Journal Article
Open access
RPRuth T. Valencia Portillo
Ruth T. Valencia Portillo
BUBernardina Amorín Uscata
Bernardina Amorín Uscata
FGFernando A Gonzales-Zubiate
Fernando A Gonzales-Zubiate
KMKatia Juscamaita Medina
Katia Juscamaita Medina
OSOrlando Sevillano
Orlando Sevillano
ESEduardo Milton Ramos Sanchez
Eduardo Milton Ramos Sanchez
La enfermedad respiratoria COVID-19 causada por el virus SARS-Cov-2 cuenta con más de 18 millones de personas infectadas y más de 600 mil muertes en el mundo, en Ecuador se tienen ya más de 88 mil infectados. Siendo el cuarto país con menos pruebas de diagnóstico realizadas, Ecuador podría afrontar un retraso en la investigación epidemiología y una ausencia de datos reales de la población afectada. Se cuenta con dos tipos de pruebas para el diagnóstico de SARS-CoV-2: las pruebas moleculares que son el Gold estándar y que se basan en la detección del virus (qRT-PCR y RT-LAMP) y las pruebas rápidas que detectan anticuerpos generados por la respuesta inmunológica del paciente. Ambas pruebas presentan pros y contras que las hacen complementarias y aumentan su alcance, ya que el foco poblacional es distinto. Las pruebas moleculares pueden detectar la presencia del virus en media, una semana antes y hasta una semana después de la aparición de los síntomas. Sin embargo, qué ocurre con los individuos asintomáticos que no fueron sometidos a ningún tipo de prueba diagnóstica y que ignoran si fueron infectados o no, y en qué momento fueron infectados. Para este grupo existen las pruebas rápidas, pruebas que detectan la respuesta inmunológica del individuo. Es así como las pruebas de diagnóstico se convierten en herramientas de vital importancia, complementando los estudios de los cuadros clínicos y la búsqueda activa de personas asintomáticas que ya pasaron del pico de carga viral. Inicialmente, la cuarentena controló el número de infectados pero la dinámica económica ha obligado a la población a salir de su hogar y es por esto que en este momento se necesitan nuevas estrategias para minimizar los efectos del SARS-CoV-2. En conclusión, las pruebas rápidas serían una solución que aceleraría la identificación y aislamiento de los individuos infectados, estimando con mayor exactitud el número de contagios, lo que permitiría una mejor toma de decisiones y el desarrollo de políticas públicas para contrarrestar la presente pandemia.

23 August 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
ADAndrea Vanessa Llanos Diaz
Andrea Vanessa Llanos Diaz
MAMoisés Apolaya-Segura
Moisés Apolaya-Segura
OSOrlando Sevillano
Orlando Sevillano
Obert Marín SánchezObert Marín Sánchez
Obert Marín Sánchez
JVJacinto Joaquin Vértiz-Osores
Jacinto Joaquin Vértiz-Osores
DDDAYSI ZULEMA DIAZ-OBREGON
DAYSI ZULEMA DIAZ-OBREGON
Background: Precision nutrition and nutrigenomics have emerged as promising strategies to personalize dietary interventions according to individual genetic, metabolic, and molecular characteristics. However, the potential of nutrigenomic-guided nutraceutical interventions to modulate biological aging pathways remains poorly characterized. Objective: This study aimed to map and synthesize the available evidence from human studies evaluating personalized nutraceutical interventions based on nutrigenomic approaches and their effects on biomarkers associated with biological aging. Methods: A scoping review was conducted following the Joanna Briggs Institute methodology and PRISMA-ScR guidelines. PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched for studies published between 2021 and 2026. Eligible studies included adults aged ≥18 years receiving personalized nutraceutical interventions informed by genetic, genomic, metabolomic, or other molecular data. Outcomes included biomarkers of cellular aging, inflammation, oxidative stress, immunometabolism, and related pathways. Results: Twenty-one studies were included. Interventions involved omega-3 fatty acids, polyphenols, Nigella sativa, vitamin D, methyl-donor micronutrients, fermented papaya preparation, and other nutraceutical preparations and functional food-based interventions. Four major themes emerged: multi-omic stratification approaches, biological aging biomarkers, redox-inflammatory modulation, and applications in metabolic disorders. Most studies demonstrated favorable effects on intermediate molecular biomarkers, including inflammatory cytokines, oxidative stress markers, lipid metabolism, endothelial function, and DNA methylation signatures. However, evidence directly demonstrating slowing of biological aging through validated biomarkers such as epigenetic clocks or telomere dynamics remains limited. Conclusions: Personalized nutraceutical interventions exhibit biological plausibility for modulating pathways associated with healthy aging. Nevertheless, robust longitudinal studies incorporating validated biomarkers of biological aging and clinically meaningful outcomes are needed before their widespread implementation in precision medicine.